News
-
Enterprise Therapeutics announced that the EMA has granted orphan drug designation to the company’s ETD001 inhaled epithelial sodium channel for the treatment of cystic fibrosis. Earlier this year, the company announced that a Phase 2… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) and Upperton Pharma Solutions have announced a collaboration “designed to provide pharmaceutical and biotech companies with a seamless, end-to-end solution spanning early discovery, formulation development, preclinical support, and clinical… Read more . . .
-
Aptar Pharma has announced that its facility in Boonton, NJ, USA is now authorized to handle, store, manufacture and test DEA Schedule II and Schedule III controlled substances, adding to existing capacities for handling high potency… Read more . . .
-
Orexo has announced that it will evaluate the ability of its AmorphOX dry powder platform to create stable formulations of SVF’s LNP-encapsulated mRNA vaccines for nasal delivery. Orexo has its own pipeline of intranasal dry… Read more . . .
-
CDMO Hovione has announced that former CEO Guy Villax will succeed Stefan Doboczky as chairman of the company’s board of directors, effective April 1, 2027. Villax served as CEO from 1997 until 2022 when he… Read more . . .
-
US-based startup LionBio, which describes itself as “The Nasal Peptide Company,” has published a video announcing the company’s launch with $6 million in seed funding and nose-to-brain delivery technology developed at Columbia University developed by… Read more . . .
-
Phillips Medisize, which completed its acquisition of inhalation CDMO Vectura in 2025, has announced the acquisition of all remaining portions of the former Vectura site in Chippenham, UK. The acquisition of Vectura originally included only… Read more . . .
-
Ethris has announced topline data from a Phase 2a challenge study of ETH47 mRNA-based antiviral in adults with mild-to-moderate asthma. According to Ethris, the trial demonstrated that ETH47 “was safe, well tolerated and showed antiviral… Read more . . .
-
The Dutch Central Committee on Research Involving Human Subjects has approved Abera Bioscience’s application for a Phase 1 clinical trial of its Ab-01.12 intranasal pneumococcal vaccine, the company said. According to Abera, the dose escalation… Read more . . .
-
Drug delivery specialist CDMO Kindeva has announced the appointment of Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery. Couto was most recently COO at Vedanta Biosciences. His prior experience includes executive positions at Vedanta,… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here

